Cargando…

A Concise Review of the Multimodality Imaging Features of Renal Cell Carcinoma

The evaluation of renal cell carcinoma (RCC) is routinely performed using the multimodality imaging approach, including ultrasonography, computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET). Ultrasonography is the most frequently used imaging modality fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Morshid, Ali, Duran, Elif S, Choi, Woongsoon J, Duran, Cihan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7946646/
https://www.ncbi.nlm.nih.gov/pubmed/33728180
http://dx.doi.org/10.7759/cureus.13231
_version_ 1783663095107813376
author Morshid, Ali
Duran, Elif S
Choi, Woongsoon J
Duran, Cihan
author_facet Morshid, Ali
Duran, Elif S
Choi, Woongsoon J
Duran, Cihan
author_sort Morshid, Ali
collection PubMed
description The evaluation of renal cell carcinoma (RCC) is routinely performed using the multimodality imaging approach, including ultrasonography, computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET). Ultrasonography is the most frequently used imaging modality for the initial diagnosis of renal masses. The modality of choice for the characterization of the renal mass is multiphasic CT. Recent advances in CT technology have led to its widespread use as a powerful tool for preoperative planning, reducing the need for catheter angiography for the evaluation of vascular invasion. CT is also the standard imaging modality for staging and follow-up. MRI serves as a problem-solving tool in selected cases of undefined renal lesions. Newer MRI techniques, such as arterial spin labeling and diffusion-weighted imaging, have the potential to characterize renal lesions without contrast media, but these techniques warrant further investigation. PET may be a useful tool for evaluating patients with suspected metastatic disease, but it has modest sensitivity in the diagnosis and staging of RCC. The newer radiotracers may increase the accuracy of PET for RCC diagnosis and staging. In summary, the main imaging modality used for the characterization, staging, and surveillance of RCC is multiphasic CT. Other imaging modalities, such as MRI and PET, are used for selected indications.
format Online
Article
Text
id pubmed-7946646
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-79466462021-03-15 A Concise Review of the Multimodality Imaging Features of Renal Cell Carcinoma Morshid, Ali Duran, Elif S Choi, Woongsoon J Duran, Cihan Cureus Radiology The evaluation of renal cell carcinoma (RCC) is routinely performed using the multimodality imaging approach, including ultrasonography, computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET). Ultrasonography is the most frequently used imaging modality for the initial diagnosis of renal masses. The modality of choice for the characterization of the renal mass is multiphasic CT. Recent advances in CT technology have led to its widespread use as a powerful tool for preoperative planning, reducing the need for catheter angiography for the evaluation of vascular invasion. CT is also the standard imaging modality for staging and follow-up. MRI serves as a problem-solving tool in selected cases of undefined renal lesions. Newer MRI techniques, such as arterial spin labeling and diffusion-weighted imaging, have the potential to characterize renal lesions without contrast media, but these techniques warrant further investigation. PET may be a useful tool for evaluating patients with suspected metastatic disease, but it has modest sensitivity in the diagnosis and staging of RCC. The newer radiotracers may increase the accuracy of PET for RCC diagnosis and staging. In summary, the main imaging modality used for the characterization, staging, and surveillance of RCC is multiphasic CT. Other imaging modalities, such as MRI and PET, are used for selected indications. Cureus 2021-02-08 /pmc/articles/PMC7946646/ /pubmed/33728180 http://dx.doi.org/10.7759/cureus.13231 Text en Copyright © 2021, Morshid et al. http://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Radiology
Morshid, Ali
Duran, Elif S
Choi, Woongsoon J
Duran, Cihan
A Concise Review of the Multimodality Imaging Features of Renal Cell Carcinoma
title A Concise Review of the Multimodality Imaging Features of Renal Cell Carcinoma
title_full A Concise Review of the Multimodality Imaging Features of Renal Cell Carcinoma
title_fullStr A Concise Review of the Multimodality Imaging Features of Renal Cell Carcinoma
title_full_unstemmed A Concise Review of the Multimodality Imaging Features of Renal Cell Carcinoma
title_short A Concise Review of the Multimodality Imaging Features of Renal Cell Carcinoma
title_sort concise review of the multimodality imaging features of renal cell carcinoma
topic Radiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7946646/
https://www.ncbi.nlm.nih.gov/pubmed/33728180
http://dx.doi.org/10.7759/cureus.13231
work_keys_str_mv AT morshidali aconcisereviewofthemultimodalityimagingfeaturesofrenalcellcarcinoma
AT duranelifs aconcisereviewofthemultimodalityimagingfeaturesofrenalcellcarcinoma
AT choiwoongsoonj aconcisereviewofthemultimodalityimagingfeaturesofrenalcellcarcinoma
AT durancihan aconcisereviewofthemultimodalityimagingfeaturesofrenalcellcarcinoma
AT morshidali concisereviewofthemultimodalityimagingfeaturesofrenalcellcarcinoma
AT duranelifs concisereviewofthemultimodalityimagingfeaturesofrenalcellcarcinoma
AT choiwoongsoonj concisereviewofthemultimodalityimagingfeaturesofrenalcellcarcinoma
AT durancihan concisereviewofthemultimodalityimagingfeaturesofrenalcellcarcinoma